Collins Stewart rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 09/26/2011. Previously Collins Stewart rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 07/25/2008., when the stock price was $20.05. Since then, Alexion Pharmaceuticals, Inc. has gained 796.86% as of 12/11/2015's recent price of $179.82.
If you would have followed the previous Collins Stewart's recommendation on ALXN, you would have gained 796.85% of your investment in 2695 days.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Quest™ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.

Marked as spam